RNAi-combined nano-chemotherapeutics to tackle resistant tumors
| dc.cclicence | N/A | en |
| dc.contributor.author | Tekade, Rakesh Kumar | en |
| dc.contributor.author | Tekade, Muktika | en |
| dc.contributor.author | Kesharwani, Prashant | en |
| dc.contributor.author | D’Emanuele, Antony | en |
| dc.date.acceptance | 2016-07-02 | en |
| dc.date.accessioned | 2016-09-29T13:16:54Z | |
| dc.date.available | 2016-09-29T13:16:54Z | |
| dc.date.issued | 2016-07-02 | |
| dc.description.abstract | The merger of nanotechnology and combination chemotherapy has shown notable promise in the therapy of resistant tumors. The latest scientific attention encompasses the engagement of anticancer drugs in combination with small interfering (si)RNAs, such as VEGF, XLAP, PGP, MRP-1, BCL-2 and cMyc, to name but a few. siRNAs have shown immense promise to knockout drug resistance genes as well as to recover the sensitivity of resistant tumors to anticancer therapy. The nanotechnology approach could also protect siRNA against RNAse degradation as well as prevent off-target effects. In this article, we discuss the approaches that have been used to deliver of siRNA in combination with chemotherapeutic drugs to treat resistant tumors. We also discuss the stipulations that must be considered in formulating a nanotechnology-assisted siRNA-drug cancer therapy. | en |
| dc.exception.ref2021codes | 252b | en |
| dc.funder | The authors acknowledge the support provided by Fundamental Research Grant (FRGS) scheme of the Ministry of Higher Education, Malaysia for research on gene delivery. The authors would like to acknowledge the International Medical University, Malaysia for providing support for cancer and arthritis research. We also acknowledge internal grants to RKT. R.K.T from the IMU-JC for providing start-up financial support to our research group. | en |
| dc.identifier.citation | Tekade, R.K. et al. (2016) RNAi-combined nano-chemotherapeutics to tackle resistant tumors. Drug Discovery Today, in press http://dx.doi.org/10.1016/j.drudis.2016.06.029 | en |
| dc.identifier.doi | https://doi.org/10.1016/j.drudis.2016.06.029 | |
| dc.identifier.issn | 1359-6446 | |
| dc.identifier.uri | http://hdl.handle.net/2086/12662 | |
| dc.language.iso | en | en |
| dc.peerreviewed | Yes | en |
| dc.projectid | N/A | en |
| dc.publisher | Elsevier | en |
| dc.researchgroup | Pharmaceutical Technologies | en |
| dc.subject | nanomedicine RNAi cancer | en |
| dc.title | RNAi-combined nano-chemotherapeutics to tackle resistant tumors | en |
| dc.type | Article | en |